Evan CPA - Nexien Biopharma Chief Officer
| NXEN Stock | USD 0.01 0.01 35.00% |
Insider
Evan CPA is Chief Officer of Nexien Biopharma
| Age | 75 |
| Phone | 303 495 7583 |
| Web | https://www.nexienbiopharma.com |
Nexien Biopharma Management Efficiency
The company has return on total asset (ROA) of (5.9895) % which means that it has lost $5.9895 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (40.7045) %, meaning that it created substantial loss on money invested by shareholders. Nexien Biopharma's management efficiency ratios could be used to measure how well Nexien Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Brian Sherman | Cannara Biotech | N/A | |
| David Abitbol | Cannara Biotech | N/A | |
| Chad White | Sonoma Pharmaceuticals | 51 | |
| Alexander Schobel | Aquestive Therapeutics | 65 | |
| Etienne Ledoux | Cannara Biotech | N/A | |
| Christopher Quesenberry | Evoke Pharma | N/A | |
| Avi Krivorot | Cannara Biotech | N/A | |
| Anthony Manouk | Cannara Biotech | N/A | |
| Julia Bouvet | Cannara Biotech | N/A | |
| France Landry | Cannara Biotech | N/A | |
| BSBA Esq | Aquestive Therapeutics | 66 | |
| Zohar Krivorot | Cannara Biotech | 46 | |
| Alexander Wolfe | Cannara Biotech | N/A | |
| Eric Dadey | Aquestive Therapeutics | N/A | |
| Kenneth MD | Aquestive Therapeutics | N/A | |
| Victoria Covel | Sonoma Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 |
Nexien Biopharma Leadership Team
Elected by the shareholders, the Nexien Biopharma's board of directors comprises two types of representatives: Nexien Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nexien. The board's role is to monitor Nexien Biopharma's management team and ensure that shareholders' interests are well served. Nexien Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nexien Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Morgan, Consultant | ||
| Esq JD, Chief Officer | ||
| Richard Greenberg, CEO, Founder | ||
| Evan CPA, Chief Officer | ||
| Paul Wilkenson, Consultant | ||
| Linda Klumpers, Consultant |
Nexien Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Nexien Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -40.7 | |||
| Return On Asset | -5.99 | |||
| Current Valuation | 2.58 M | |||
| Shares Outstanding | 62.77 M | |||
| Shares Owned By Insiders | 54.17 % | |||
| Price To Book | 205.41 X | |||
| EBITDA | (563.99 K) | |||
| Net Income | (626.36 K) | |||
| Cash And Equivalents | 116.9 K | |||
| Total Debt | 221.73 K |
Pair Trading with Nexien Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nexien Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nexien Biopharma will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Nexien Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nexien Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nexien Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nexien Biopharma to buy it.
The correlation of Nexien Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nexien Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nexien Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nexien Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.